undamentalytics Newsletter
Sign in

Therapeuticsmd, Inc. revenue

Therapeuticsmd, Inc.'s revenue was $3.0m in fiscal 2025, up 71.6% on the year before. Since fiscal 2011 ($2.1m) it has grown at a compound 2.7% a year. Over the last twelve months it was $3.3m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue249152019171650653701233
Growth on the year before—+82.8%+129.8%+71.2%+34.1%−3.9%−13.3%−4.0%+208.4%+30.7%−96.0%+>999%−98.1%+35.3%+71.6%—
Gross profit127111615141343491691———
Gross margin54.6%64.7%77.7%75.6%77.6%78.4%84.3%83.0%87.2%75.4%45.5%98.0%100.0%———

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
United States $1.8M 59.3% ▲ 59.6%
Outside the US $1.2M 40.7% ▲ 92.8%

From Therapeuticsmd, Inc.'s 10-K filed March 30, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Therapeuticsmd, Inc. $3.3m 27.8% -63.9%
Eyepoint, Inc. $2.8m -94.6% -57.9%
China Pharma Holdings, Inc. $3.9m -11.0% -21.0%
Nutriband Inc. $1.6m -37.3% -10.8%
Lipocine Inc. $1.6m -62.7% 205.6%
China SXT Pharmaceuticals, Inc. $1.1m -34.6% —

Compare with peers

Head to head: EYPT vs TXMDCPHI vs TXMDNTRB vs TXMD

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Therapeuticsmd, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Therapeuticsmd, Inc.